PMID- 22127531
OWN - NLM
STAT- MEDLINE
DCOM- 20120821
LR  - 20211203
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
VI  - 42
IP  - 5
DP  - 2012 May
TI  - mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time 
      fluorescence quantitative polymerase chain reaction and immunohistochemistry.
PG  - 419-25
LID - 10.1007/s00595-011-0028-1 [doi]
AB  - PURPOSE: To detect the expression of mammalian target of rapamycin (mTOR) and 
      PTEN in non-small cell lung cancer (NSCLC), and explore their role in the 
      prognosis of patients with NSCLC. METHODS: Samples of cancer tissues and normal 
      lung tissues from 78 patients with NSCLC were examined for expression of mTOR and 
      PTEN by real-time polymerase chain reaction and immunohistochemistry. The 
      differences in mTOR and PTEN expression were compared by Student's t test. A Cox 
      regression model was used to analyze the relationship between the influencing 
      factors and the prognosis. Kaplan-Meier survival curves and the log-rank test 
      were used to analyze the progression-free survival. RESULTS: The mTOR expression 
      in NSCLC tissues was significantly higher than that in normal lung tissue, while 
      the levels of PTEN expression in NSCLC tissue were significantly lower than that 
      in normal lung tissues (P < 0.05). No significant correlations were observed 
      between the mTOR and PTEN expressions and the patients' age, sex, pathological 
      type, differentiation, lymph node metastasis, or distant metastasis. The only 
      correlation was with the T stage. The Cox regression analysis showed that mTOR 
      and PTEN expression had an important impact on the patient prognosis. 
      CONCLUSIONS: The absence of and/or a low expression of PTEN and activated mTOR 
      may play an important role in the development of NSCLC, and may represent new 
      prognostic biomarkers for a poor prognosis in patients with NSCLC.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Thoracic Surgery, Beijing Chest Hospital, Affiliated to Capital 
      Medical University, Beijing, 101149, People's Republic of China.
FAU - Yue, Wentao
AU  - Yue W
FAU - Zhang, Lina
AU  - Zhang L
FAU - Zhao, Xiaoting
AU  - Zhao X
FAU - Wang, Yue
AU  - Wang Y
FAU - Xu, Shaofa
AU  - Xu S
LA  - eng
PT  - Journal Article
DEP - 20111130
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adenocarcinoma/metabolism/mortality/pathology/secondary
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/mortality/pathology/secondary
MH  - Carcinoma, Squamous Cell/metabolism/mortality/pathology/secondary
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*metabolism/mortality/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - PTEN Phosphohydrolase/*metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Real-Time Polymerase Chain Reaction
MH  - TOR Serine-Threonine Kinases/*metabolism
EDAT- 2011/12/01 06:00
MHDA- 2012/08/22 06:00
CRDT- 2011/12/01 06:00
PHST- 2010/11/30 00:00 [received]
PHST- 2011/04/12 00:00 [accepted]
PHST- 2011/12/01 06:00 [entrez]
PHST- 2011/12/01 06:00 [pubmed]
PHST- 2012/08/22 06:00 [medline]
AID - 10.1007/s00595-011-0028-1 [doi]
PST - ppublish
SO  - Surg Today. 2012 May;42(5):419-25. doi: 10.1007/s00595-011-0028-1. Epub 2011 Nov 
      30.